The concept of autogenes has been proposed recently, and experimental autoimmune
diseases have been considered as “polyclonal stem cell diseases”. Autoantibodies …

▪ Abstract The prevalence of autoimmune diseases (ADs) in Western countries is estimated
to be from 3–7%, and the treatment of severe, relapsing/refractory cases is still not …

Over the past 10 years a coordinated program has been running internationally under the
auspices of the European Group for Blood and Marrow Transplantation (EBMT), the …

Among the over 40 disorders recognized at present as having an autoimmune pathogenesis
[1, 21 there are a significant number of severe diseases which can only be partially …

Patients afflicted by an autoimmune disorder have generally been considered to have a
normal life expectancy complicated by a relapsing/remitting or chronic disease. However …

Internationally 397 patients (310 in Europe/Austalasia and 87 in North America) with severe
autoimmune disease (AD) have received an autologous haemopoietic stem cell transplant …

Clinical results Post-transplant autoimmunity. The term adoptive autoimmunity was
proposed in 1992 to indicate the transfer of an autoimmune disorder from a HSC donor to a …

The past year of activities represents virtually the first year of activities in hemopoietic blood
and marrow transplants in the treatment of severe autoimmune disease. The concept of …

An international co-ordinated Phase I/II program commenced 8 years ago to study the role of
profound immunoablation with hematopoietic stem cell transplantation in the treatment of …

Ten years have passed since the first published consensus statement on the use of
hematopoietic stem cell transplantation (HSCT) in the treatment of severe autoimmune …